The European Commission (EC) has granted marketing authorisation for Tepkinly (epcoritamab) in combination with lenalidomide and rituximab (R2) for the treatment of relapsed or refractory follicular lymphoma. The combination regimen, developed by AbbVie and Genmab for the treatment of adult patients, is the first and only bispecific-based therapy approved in Europe for the treatment of relapsed or refractory […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!